Mechanism of Reactive Oxygen/Nitrogen Species in Liver Ischemia-Reperfusion Injury and Preventive Effect of Chinese Medicine.
10.1007/s11655-024-3810-9
- Author:
Lei GAO
1
;
Yun-Jia LI
2
;
Jia-Min ZHAO
1
;
Yu-Xin LIAO
1
;
Meng-Chen QIN
1
;
Jun-Jie LI
1
;
Hao SHI
1
;
Nai-Kei WONG
3
;
Zhi-Ping LYU
1
;
Jian-Gang SHEN
4
Author Information
1. School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510515, China.
2. The First Affiliated Hospital/the First Clinical Medicine School of Guangdong Pharmaceutical University, Guangzhou, 510006, China.
3. State Key Discipline of Infectious Diseases, Shenzhen Third People's Hospital, the Second Affiliated Hospital, Shenzhen University, Shenzhen, 518112, Guangdong Province, China.
4. School of Chinese Medicine, the University of Hong Kong, Hong Kong SAR, China. shenjg@hku.hk.
- Publication Type:Review
- Keywords:
Chinese medicine;
ischemia-reperfusion injury;
liver;
nitrogen;
oxygen;
review
- MeSH:
Reperfusion Injury/drug therapy*;
Reactive Oxygen Species/metabolism*;
Reactive Nitrogen Species/metabolism*;
Humans;
Liver/drug effects*;
Animals;
Medicine, Chinese Traditional;
Drugs, Chinese Herbal/pharmacology*
- From:
Chinese journal of integrative medicine
2025;31(5):462-473
- CountryChina
- Language:English
-
Abstract:
Liver ischemia-reperfusion injury (LIRI) is a pathological process involving multiple injury factors and cell types, with different stages. Currently, protective drugs targeting a single condition are limited in efficacy, and interventions on immune cells will also be accompanied by a series of side effects. In the current bottleneck research stage, the multi-target and obvious clinical efficacy of Chinese medicine (CM) is expected to become a breakthrough point in the research and development of new drugs. In this review, we summarize the roles of reactive oxygen species (ROS) and reactive nitrogen species (RNS) in various stages of hepatic ischemia-reperfusion and on various types of cells. Combined with the current research progress in reducing ROS/RNS with CM, new therapies and mechanisms for the treatment of hepatic ischemia-reperfusion are discussed.
